Toxic Effects of Metallopharmaceuticals

1. Jakupec MA, Galanski M, & Keppler BK. (2003). Tumour- inhibiting platinum complexes--state of the art and future perspectives. Reviews of Physiology, Biochemistry and Pharmacology, 146, 1-54. 10.1007/s10254-002-0001-xSearch in Google Scholar

2. Sakurai H. (2010). Overview and frontier for the development of metallopharmaceutics. Journal of Health Science, 56(2), 129-143.10.1248/jhs.56.129Open DOISearch in Google Scholar

3. Clarke MJ, Zhu F, & Frasca DR. (1999). Non-platinum chemotherapeutic metallopharmaceuticals. Chemical Reviews, 99(9), 2511-2534.10.1021/cr9804238Search in Google Scholar

4. Donzelli E, Carfi M, Miloso M, Strada A, Galbiati S, Bayssas M, Griffon-Etienne G, Cavaletti G, Petruccioli MG, & Tredici G. (2004). Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SHSY5Y. Journal of Neuro-oncology, 67(1-2), 65-73.10.1023/B:NEON.0000021787.70029.ceSearch in Google Scholar

5. Allardyce CS, & Dyson PJ. (2001). Ruthenium in medicine: current clinical uses and future prospects. Platinum Metals Review, 45(2), 62-69.Search in Google Scholar

6. van Rijt SH, & Sadler PJ (2009). Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discovery Today, 14(23), 1089-1097.10.1016/j.drudis.2009.09.003Open DOISearch in Google Scholar

7. Kelland L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer 7(8), 573-584.10.1038/nrc2167Open DOISearch in Google Scholar

8. Stachurska A, Dudkowska M, Czopek A, Manteuffel- Cymborowska M, & Grzelakowska-Sztabert B. (2004). Cisplatin up-regulates the in vivo biosynthesis and degradation of renal polyamines and c-Myc expression. Biochimica et Biophysica Acta, 1689(3), 259-266.10.1016/j.bbadis.2004.04.003Search in Google Scholar

9. Cassidy J, & Misset JL. (2002). Oxaliplatin-related side effects: characteristics and management. Seminars in Oncology, 29(5 Suppl 15), 11-20.10.1053/sonc.2002.35524Open DOISearch in Google Scholar

10. Yao X, Panichpisal K, Kurtzman N, & Nugent K. (2007). Cisplatin nephrotoxicity: a review. The American Journal of the Medical Sciences, 334(2), 115-124.10.1097/MAJ.0b013e31812dfe1eSearch in Google Scholar

11. Goldstein RS, & Mayor GH. (1983). The nephrotoxicity of cisplatin. Life Sciences, 32(7), 685-690. 10.1016/0024-3205(83)90299-0Open DOISearch in Google Scholar

12. Kroning R, Katz D, Lichtenstein AK, & Nagami GT. (1999). Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines. British Journal of Cancer, 79(2), 293-299.10.1038/sj.bjc.6690047Open DOISearch in Google Scholar

13. Fjeldborg P, Sorensen J, & Helkjaer PE. (1986). The long-term effect of cisplatin on renal function. Cancer, 58(10), 2214-2217.10.1002/1097-0142(19861115)58:10<2214::AID-CNCR2820581009>3.0.CO;2-ISearch in Google Scholar

14. Daugaard G, Rossing N, & Rorth M. (1988). Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemotherapy and Pharmacology, 21(2), 163-167.10.1007/BF00257365Search in Google Scholar

15. Moul JW, Robertson JE, George SL, Paulson DF, & Walther PJ. Complications of therapy for testicular cancer. (1989). The Journal of Urology, 142(6), 1491-1496. 10.1016/S0022-5347(17)39135-8Search in Google Scholar

16. Keppler BK, Henn M, Juhl U M, Berger MR, Niebl R, & Wagner FE. (1989). New ruthenium complexes for the treatment of cancer. In Baulieu E, Forman DT, Ingelman- Sundberg M, Jaenicke L, Kellen JA, Nagai Y, Springer GF, Trager T, Will-Shahab L,Wittliff JL (Eds.) Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy (pp. 41-69). Springer Berlin Heidelberg.10.1007/978-3-642-74760-1_3Search in Google Scholar

17. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L, & Cavaletti G. (1999). Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology, 20(6), 883-887.Search in Google Scholar

18. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, & Standefer JC. (1984). Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer, 54(7), 1269-1275.10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9Open DOISearch in Google Scholar

19. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, & Belinson J. (2001). Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. Journal of Cancer Research and Clinical Oncology, 127(1), 55-58. 10.1007/s004320000157Search in Google Scholar

20. Gamelin E, Gamelin L, Bossi L, & Quasthoff S. (2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Seminars in Oncology, 29(5), 21-33.10.1016/S0093-7754(02)90017-5Search in Google Scholar

21. Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, & Gamelin, E. (2004). Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions A Retrospective Study of 161 Patients Receiving Oxaliplatin Combined with 5-Fluorouracil and Leucovorin for Advanced Colorectal Cancer. Clinical Cancer Research, 10(12), 4055-4061.10.1158/1078-0432.CCR-03-0666Search in Google Scholar

22. Ding D, Allman BL, & Salvi R. (2012). Review: ototoxic characteristics of platinum antitumor drugs. Anatomical Record (Hoboken, N.J.: 2007). 295(11), 1851-1867.10.1002/ar.22577Search in Google Scholar

23. Ravi R, Somani SM, & Rybak LP. (1995). Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacology & Toxicology, 76(6), 386-394.10.1111/j.1600-0773.1995.tb00167.xOpen DOISearch in Google Scholar

24. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, & Kanz L. (1998). Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. British Journal of Cancer, 77(8), 1355-1362.10.1038/bjc.1998.22621501489579846Search in Google Scholar

25. Reddel RR, Kefford RF, Grant J M, Coates AS, Fox RM, & Tattersall M H. (1982). Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports, 66(1), 19-23.Search in Google Scholar

26. Skinner R, Pearson AD, Amineddine HA, Mathias DB, & Craft AW. (1990). Ototoxicity of cisplatinum in children and adolescents. British Journal of Cancer, 61(6), 927-933.10.1038/bjc.1990.20819716782372498Search in Google Scholar

27. Deavall DG, Martin EA, Horner JM, & Roberts R. (2012). Drug-induced oxidative stress and toxicity. Journal of Toxicology, 2012, 645460.10.1155/2012/645460342013822919381Search in Google Scholar

28. van der Hulst RJ, Dreschler WA, & Urbanus NA. (1988). High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Annals of Otology, Rhinology & Laryngology, 97(2 Pt 1), 133-137.10.1177/0003489488097002083281541Search in Google Scholar

29. Hansen SW, & Olsen N. (1989). Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: Measurement of vasoconstrictor response to cold. Journal of Clinical Oncology, 7(7), 940-942.10.1200/JCO.1989.7.7.9402472472Open DOISearch in Google Scholar

30. Vogelzang NJ, Bosl GJ, Johnson K, & Kennedy BJ. (1981). Raynaud’s phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Annals of Internal Medicine, 95(3), 288-292.10.7326/0003-4819-95-3-2886168223Search in Google Scholar

31. Masuda H, Tanaka T, & Takahama U. (1994). Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochemical and Biophysical Research Communications, 203(2), 1175-1180.10.1006/bbrc.1994.23068093036Search in Google Scholar

32. Santos NAG, Catao CS, Martins NM, Curti C, Bianchi MLP, & Santos AC. (2007). Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Archives of Toxicology, 81(7), 495-504.10.1007/s00204-006-0173-217216432Open DOISearch in Google Scholar

33. Stojic I, Zivkovic V, Srejovic I, Jeremic N, Jakovljevic V, Djuric D, & Novokmet, S. (2016). The Effects of Cisplatin and Its Pt(II) Analogue on Oxidative Stress of Isolated Rat Heart. Serbian Journal of Experimental and Clinical Research, 17(1), 15-20.10.1515/sjecr-2015-0050Search in Google Scholar

34. Misic MM, Jakovljevic VL, Bugarcic ZD, Zivkovic VI, Srejovic IM, Barudzic NS, Djuric DM, & Novokmet SS. (2015). Platinum Complexes-Induced Cardiotoxicity of Isolated, Perfused Rat Heart: Comparison of Pt(II) and Pt(IV) Analogues Versus Cisplatin. Cardiovascular Toxicology, 15(3), 261-268.10.1007/s12012-014-9293-825404470Search in Google Scholar

35. Dougan SJ, Habtemariam A, McHale SE, Parsons S, & Sadler PJ. (2008). Catalytic organometallic anticancer complexes. Proceedings of the National Academy of Sciences, 105(33), 11628-11633.10.1073/pnas.0800076105250392418687892Search in Google Scholar

36. Levina A, Mitra A, & Lay PA. (2009). Recent developments in ruthenium anticancer drugs. Metallomics, 1(6), 458-470.10.1039/b904071d21305154Search in Google Scholar